Eagle Pharmaceuticals Inc. said the FDA issued a complete response letter (CRL) for Kangio (bivalirudin injection), which the company is advancing through the 505(b)(2) pathway as a ready-to-use, stable liquid intravenous formulation of 5 mg/mL bivalirudin, a new version of the anticoagulant Angiomax (bivalirudin, The Medicines Co.).